The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Pfizer reported strong Phase 3 oncology data for BRAFTOVI, TALZENNA, and LORBRENA, demonstrating improved survival rates across multiple cancers. The company also announced positive mid-stage results for berobenatide, an obesity therapy, with plans for 10 Phase 3 trials to develop the first monthly GLP-1 treatment. Furthermore, Pfizer secured new FDA approvals alongside significant acquisition and collaboration activity involving other industry giants like Johnson & Johnson and Roche.